[The significance of somatostatin for decreasing peri- and postoperative complications in Whipple operation].
During the period from 1987-1990 152 patients underwent a Whipple procedure at the Department of General Surgery of Münster University Hospital. 27 operations were performed for chronic pancreatitis (17.8%), 52 for pancreatic (34.2%) and 73 (48.0%) for ampullary carcinoma. All patients received Somatostatin (6 mg/24 h) postoperatively for five days. These patients were compared with those of a former series who were identically operated but did not receive Somatostatin. In-hospital-mortality was reduced from 10.7% to 4.6%. Additionally the frequency of postoperative pancreatic fistulas was reduced among the nonlethal complications.
Klinik und Poliklinik für Allgemeine Chirurgie, Westfälischen Wilhelms-Universität Münster, Bundesrepublik Deutschland.
J
J
Meyer
P
P
Preusser
H
H
Bünte
D014670:Ampulla of Vater / Q000601:surgery*; D002908:Chronic Disease; D003138:Common Bile Duct Neoplasms / Q000601:surgery*; D006801:Humans; D007260:Infusion Pumps; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000601:surgery*; D010193:Pancreaticojejunostomy; D010195:Pancreatitis / Q000601:surgery*; D011183:Postoperative Complications / Q000517:prevention & control*; D013004:Somatostatin / Q000008:administration & dosage*
D013004:Somatostatin
Die Bedeutung des Somatostatins für die Senkung der peri- und postoperativen Komplikationen bei der Whipple-Operation.